Extraintestinal manifestations of inflammatory bowel disease: Focus on the musculoskeletal, dermatologic, and ocular manifestations

MedGenMed Medscape General Medicine

Volumn 9, Issue 1, 2007, Pages

  Evans, Paul E ^a   Pardi, Darrell S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; BEHAVIOR MODIFICATION; BONE DENSITY; BONE MINERAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; EXERCISE; EYE DISEASE; HUMAN; INFLAMMATION; JOINT RADIOGRAPHY; LIFESTYLE; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; PREVALENCE; PYODERMA GANGRENOSUM; RISK ASSESSMENT; SACROILIAC JOINT; SACROILIITIS; SCLERITIS; SKIN BIOPSY; SKIN DISEASE; SPINE; SPINE RADIOGRAPHY; SPONDYLOARTHROPATHY; UNSPECIFIED SIDE EFFECT; UVEITIS; DISEASE MANAGEMENT; METABOLIC BONE DISEASE; MUSCLE DISEASE; PATHOPHYSIOLOGY; REVIEW;

BONE DISEASES, METABOLIC; DISEASE MANAGEMENT; EYE DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; MUSCULAR DISEASES; SKIN DISEASES;

EID: 33947417284     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case control study. Inflamm Bowel Dis. 2004;10:207-214.
2. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease: A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34.
3. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province or western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9:2300-2307.
4. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn Colitis Database. Am J Gastroenterol. 2006;101:1274-1282.
5. Nguyen G, Torres EA, Reguiero M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and Non-Hispanic whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012-1023.
6. Salvarani C, Vlachonikolis IG, van der Heijde DM, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;12:1307-1313.
7. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819-4831.
8. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387-391.
9. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122.
10. Manguso F, Sanges M, Staiano T, et al. Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol. 2004;99:327-334.
11. Schur PH. Arthritis associated with gastrointestinal disease. UpToDate; 2006.
12. Scott WW Jr, Fishman EK, Kuhlman JE, et al. Computed tomography evaluation of the sacroiliac joints in Crohn's disease. Skeletal Radiol. 1990;19:207-210.
13. Reinisch W, Miehsler W, Dejaco C, et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther. 2003;17:1371.
14. Guslandi M. Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction? World J Gastroenterol. 2006;12:1509-1510.
15. Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995;38:618-627.
16. Maksymowych WP, Inman RD, Gladman D, et al. Canadian Rheumatology Association consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol. 2003;30:1356-1363.
17. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002;359:1187-1193.
18. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002:346:1349-1356.
19. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667-1675.
20. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:2224-2233.
21. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two week open-label trial. Arthritis Rheum. 2006;54:678-681.
22. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133:795-799.
23. Lichtenstein GR, Sands BE, Pazianis M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:797-813.
24. American Gastroenterological Association Medical Position Statement: Guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:791-794.
25. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's disease study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914-920.
26. Loftus EV. Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep. 2004;6:506-513.
27. Veloso FT. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(suppl 4):50-53.
28. Clayton TH, Walker BP, Stables GI. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol. 2006;31:818-825.
29. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-1826.
30. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580-585.
31. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135-139.